-

Stevanato Group to Participate in Upcoming Investor Conferences

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in two upcoming investor conferences.

  • Monday, November 17, 2025, at 8:40 a.m. ET - The 7th Annual Wolfe Research Healthcare Conference in New York City
  • Wednesday, November 19, 2025, at 11:00 a.m. GMT - The Jefferies Global Healthcare Conference in London

A live webcast of each event will be available on the Company’s website at www.stevanatogroup.com under the "Investors" section. Replays will remain available for approximately 90 days after each event.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical, and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value-added solutions to clients.

For more information, please visit: www.stevanatogroup.com.

Contacts

Investor Relations
Lisa Miles
lisa.miles@stevanatogroup.com
Giacomo Guiducci
giacomo.guiducci@stevanatogroup.com

Media
Caterina Tripepi
caterina.tripepi@stevanatogroup.com

Stevanato Group S.p.A.

NYSE:STVN

Release Versions

Contacts

Investor Relations
Lisa Miles
lisa.miles@stevanatogroup.com
Giacomo Guiducci
giacomo.guiducci@stevanatogroup.com

Media
Caterina Tripepi
caterina.tripepi@stevanatogroup.com

More News From Stevanato Group S.p.A.

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026. Second Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €302.0 million, with high-value solutions representing 45% of total revenue. Gross profit margin increase...

Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Group’s proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Mark...

Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2026 on Tuesday, August 4, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Tuesday, August 4, 2026, to discu...
Back to Newsroom